retatrutide ly3437943 phase 2 trial obesity nejm 2023 𧬠R3TA is a next-generation peptide being studied for its unique triple-receptor approach to metabolic health. Unlike traditional GLP-1 therapies, R3TA is designed to interact with three metabolic pathways simultaneously: GLP-1, GIP Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Description
Diabetes 63 (10), 32213229
The result: a stable, scalable product that meets Fridays needs today and allows growth
The study also confirmed that AOD9604 works by inhibiting fat synthesis in liver and fat cells, providing additional mechanistic insight into how the peptide promotes metabolic health
The body does not burn fat uniformly
He did his PhD under the supervision of A.A
